Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease which can
induce progressive disability if not properly treated early. Over the last 20 years, the …

Background: The treatment of rheumatoid arthritis (RA), a chronic systemic inflammatory
autoimmune disease, is based on disease-modifying anti-rheumatic drugs (DMARDs) …

Importance Biosimilar drugs are potentially lower-cost versions of biologics that may
improve access to therapy. However, there is a lack of adequate systematic reviews …

The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the
emergence of new bDMARDs against different therapeutic targets and biosimilars have …

Anti-tumour necrosis factors (anti-TNFs) are established as first-line biological therapy for
rheumatoid arthritis (RA) with over two decades of accumulated clinical experience. Anti …

Background There are limited data regarding efficacy of abatacept treatment for rheumatoid
arthritis (RA) outside clinical trials. Quality registers have been useful for observational …

The current treatment approach in rheumatoid arthritis (RA) follows a stepwise management,
starting from early introduction of conventional synthetic (cs) disease-modifying anti …

Objectives There are few comparative data for tumor necrosis factor inhibitors in patients
with rheumatoid arthritis (RA). Methods Historical data for reference product/biosimilar …

Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease characterized by
persistent joint synovial inflammation and swelling, leading to cartilage damage and bone …

To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective
cohort (RECORD Study of Italian Society for Rheumatology) study on administrative …